Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors – FierceBiotech

The immune pathway known as stimulator of interferon genes (STING) has long been of interest in the oncology community because activating it creates an inflammatory environment that should improve the ability of immune cells to attack cancer. But experimental STING-activating treatments have produced mixed results in clinical trials.
Researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center have promising evidence that adding STING activators to CAR-T cell therapies…

Click here to view the original article.